Even at a steep discount, the list prices of new adalimumab biosimilars are significantly higher than the original price of the originator product (Humira), highlighting how dramatically its list ...

July 18 (Reuters) - A close copy version of Abbvie's (ABBV.N), opens new tab blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital ...

The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...

The best-selling drug in the world isn’t worth its current price—and isn’t as good at its job as two of its potential competitors. That’s the conclusion of the Institute for Clinical and Economic ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

Drugmaker Boehringer Ingelheim and prescription savings platform GoodRx have teamed up to provide Boehringer’s Humira biosimilar for an exclusive cash price on GoodRx, the companies announced Thursday ...

An announcement early this month by Mark Cuban’s deep discount drug company that it would sell Coherus Biosciences’ biosimilar version of AbbVie’s Humira has the Illinois drugmaker calling foul. In a ...

June 1 (Reuters) - Coherus BioSciences Inc (CHRS.O), opens new tab said on Thursday it plans to launch a biosimilar of AbbVie Inc's (ABBV.N), opens new tab Humira in July at a list price of $995 per ...

In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie managed to hang on to most of ...